广济药业(000952) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2021 was ¥153,025,444.18, a decrease of 11.06% compared to the same period last year[3] - Net profit attributable to shareholders was ¥14,463,917.06, down 49.90% year-on-year, while net profit after deducting non-recurring gains and losses was ¥13,131,191.41, a decrease of 52.88%[3] - The company's basic earnings per share for Q3 2021 were ¥0.0420, a decrease of 51.16% compared to the same period last year[3] - Total operating revenue for the current period is ¥476,334,358.27, a decrease of 7.1% compared to ¥512,925,865.11 in the previous period[19] - Net profit for the current period increased to ¥70,762,725.31, up 59.3% from ¥44,369,986.06 in the previous period[20] - Operating profit rose to ¥82,547,084.84, an increase of 16.5% compared to ¥70,831,626.07 in the previous period[20] - Total comprehensive income for the current period was ¥70,728,188.49, compared to ¥44,395,546.45 in the previous period, reflecting a significant increase[21] - Basic and diluted earnings per share improved to ¥0.2156 from ¥0.1443, representing a growth of 49.4%[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,029,161,380.53, reflecting a 2.51% increase from the end of the previous year[3] - The company's current assets totaled RMB 732,838,471.74, compared to RMB 702,078,108.43 at the end of 2020, indicating an increase of about 4.4%[16][18] - Accounts receivable rose to RMB 113,378,501.30 from RMB 104,126,189.56, representing an increase of approximately 8.7% year-over-year[16][18] - Inventory increased significantly to RMB 205,156,089.94, up from RMB 163,573,855.70, marking a growth of around 25.5%[16][18] - Short-term borrowings increased to RMB 246,510,580.00 from RMB 203,636,855.83, which is an increase of approximately 21%[17][18] - Total liabilities decreased slightly to RMB 613,383,385.69 from RMB 613,748,833.05, showing a marginal decline of about 0.6%[18] Investment and Income - The company reported a significant increase in investment income, reaching ¥18,805,394.72, a rise of 771.08% year-on-year due to debt restructuring gains[9] - The company's long-term equity investments increased by 113.82% to ¥32,848,471.83, attributed to the net asset increase of its joint venture[8] - The long-term equity investment increased to RMB 32,848,471.83 from RMB 15,362,437.12, indicating a growth of approximately 113.5%[16][18] Expenses - The company experienced a 28.87% reduction in selling expenses, amounting to ¥15,582,715.46, due to changes in revenue recognition standards[8] - Total operating costs decreased to ¥419,085,867.85 from ¥448,296,054.86, reflecting a reduction of 6.5%[19] - Research and development expenses slightly decreased to ¥28,975,921.78 from ¥29,823,985.63, a decline of 2.8%[20] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥70,403,789.39, down 35.26% compared to the same period last year[9] - Cash flow from operating activities generated a net amount of ¥70,403,789.39, down 35.2% from ¥108,749,008.81 in the previous period[24] - Cash and cash equivalents at the end of the period totaled ¥312,683,285.79, a decrease from ¥318,945,914.90 in the previous period[25] - Investment activities resulted in a net cash outflow of ¥39,001,358.06, compared to a larger outflow of ¥195,503,465.94 in the previous period[25] Corporate Developments - The company announced a strategic cooperation agreement with China National Pharmaceutical Group Hubei Co., Ltd. in the field of raw materials and pharmaceutical formulations[13] - The completion date for the annual production of 1,000 tons of Vitamin B12 project has been postponed to December 30, 2022[13] Shareholder Information - The total equity attributable to shareholders was ¥1,426,584,501.63, an increase of 3.90% from the previous year[4] - The number of ordinary shareholders at the end of the reporting period was 29,237[11] Reporting Standards - The third quarter report of Hubei Guangji Pharmaceutical Co., Ltd. is unaudited[27] - The new lease accounting standards were first implemented in 2021, with retrospective adjustments made to prior comparative data[27] - The board of directors announced the third quarter report on October 21, 2021[27]